Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 419-428

  Alahari, Suresh K ^a   Delong, Robert ^a   Fisher, Michael H ^a   Dean, Nicholas M ^b   Viliet, Pierre ^b   Juliano, R L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTISENSE OLIGONUCLEOTIDE; GLYCOPROTEIN P; LIPOFECTIN; OLIGONUCLEOTIDE; PHOSPHOROTHIOATE 2' METHOXYETHOXY OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; FLOW CYTOMETRY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3T3 CELLS; ANIMALS; MICE; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN;

EID: 0031849610     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Agrawal S (1996) Antisense oligonucleotides: Towards clinical trials. Trends Biotechol 14:376-378.
2. Akhtar S and Juliano RL (1992) Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol 2:139-143.
3. Alahari SK, Dean NM, Fisher MH, DeLong R, Manoharan M, Tivel KL and Juliano RL (1996) Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 50:808-819.
4. Bennett CF, Chiang MY, Chan H, Shoemaker JE and Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate oligonucleotides. Mol Pharmacol 41:1023-1033.
5. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA and Baker JRJ (1996) Regulation of In vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24:2176-2182.
6. Bradley G and Ling V (1994) P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 13:223-233.
7. Chabner BA and Wilson W (1991) Reversal of multidrug resistance. J Clin Oncol 9:4-6.
8. Citro G, Perrotti D, Cucco C, D'Agnano I, Sacchi A, Zupi G and Calabretta B (1992) Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:7031-7035.
9. Corrias MV and Tonini GP (1992) An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res 12:1431-1438.
10. Crooke ST and Bennett CF (1996) Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107-129.
11. Dalton WS (1994) Is P-glycoprotein a potential target for reversing clinical drug resistance? Curr Opin Oncol 6:595-600.
12. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR and Bonnet JD (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. Cancer 75:815-820.
13. Dean NM and McKay R (1994) Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:117662-11766.
14. DeLong R, Stephenson K, Loftus T, Alahari SK, Fisher MH and Juliano RL (1997) Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci 86:762-764.
15. Efferth T and Volm M (1993) Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50:303-308.
16. Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R and Raffeld M (1994) Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J Clin Invest 94:1736-1746.
17. Feigner PL and Ringold GM (1989) Cationic liposome mediated transfection. Nature 337:387-388.
18. Haensler J and Szoka FCJ (1993) Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 4:372-279.
19. Helene C and Toulme JJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99-125.
20. Higgins KA, Perez JR, Coleman A, Dorshkind K, McComas AA, Sarimento UM, Rosen CA and Narayanan R (1993) Antisense inhibition of the p65 subunit of NK-kB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901-9905.
21. Hughes JA, Avrutskaya AV, Aronson A and Juliano RL (1996) Evaluation of adjuvants that enhance the effectiveness of antisense oligonucleotides. Pharm Res 13:404-410.
22. Jaroszewski JWO, Kaplan JL, Syi M, Sehested PJ, Faustino P and Cohen JS (1990) Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun 2:287-294.
23. Kajiji S, Dreslin JA, Grizzuti K and Gros P (1994) Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochemistry 33:5041-5048.
24. Kane SE, Reinhard DH, Fordis CM, Pastan I and Gottesman M (1989) A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene 84:439-446.
25. Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C and Cook PD (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 36:831-841.
26. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C and Herrmann F (1994) Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13: 4645-4652.
27. Knecht D and Loomis WF (1987) Antisense RNA inactivation of myosin heavy chain gene expression in Dictyostelium discoideum. Science 236:1081-1086.
28. Kobayashi H, Dorai T, Holland JF and Ohnuma T (1994) Reversal of dug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 54:1271-1275.
29. Leonetti JP, Mechti N, Degols G, Gagnor C and LeBleu B (1991) Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA 88:2702-2706.
30. Leyland-Jones B, Dalton W, Fisher GA and Sikic BI (1993) Reversal of multidrug resistance to cancer chemotherapy. Cancer 72:3484-3488.
31. Licht T, Pastan I, Gottesman M and Herrmann F (1994) P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 69:159-171.
32. McKay RA, Cummins LL, Graham MJ, Lsnik EA, Owens SR, Winniman M and Dean NM (1996) Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-α by the incorporation of 2′-O-propyl modification. Nucleic Acids Res 24:411-417.
33. Milligan JF, Matteuccik MD and Martin J (1993) Current concepts in antisense drug design. Med Chem 36:1923-1937.
34. Monia BP, Johnston JF, Sasmor H and Cummins LL (1996) Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem 271:14533-14540.
35. Nesterova M and Cho-Chung YS (1995) A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1:528-533.
36. Parente RA, Nir S and Szoka FCJ (1990) Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochem 29:8720-8728.
37. Plank C, Oberhauser B, Mechtler K, Koch C and Wagner E (1994) The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem 269:12918-12924.
38. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T and Parmiani G (1990) Modulation of multidrug resistance by verapamil or MDR1 antisense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46:727-732.
39. Roninson IB (1992) The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95-102.
40. Sadownik A, Deng G, Janout V and Regen SL (1995) Rapid construction of a squalamine mimic. J Am Chem Soc 117:6138-6139.
41. Saison-Behmoaras T, Tocque B, Rey I, Chassignol M, Thuong NT and Helene C (1991) Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 10:1111-1118.
42. Scanlon KJ, Ishida H and Kashani-Sabet M (1994) Ribozyme-mediated reversal of the multidrug resistant phenotype. Proc Natl Acad Sci USA 91:11123-11127.
43. Schwab G, Chavany C, Duroux I, Goubin G, LeBeau J, Helene C and Saison-Behmoras T (1994) Antisense oligonucleotides adsorbed to polyalkyeyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 91:10460-10464.
44. Shoji Y, Akhtar S, Periasamy A, Herman B and Juliano RL (1991) Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res 19:5543-5550.
45. Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z and Calabretta B (1995) Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 186:1645-1653.
46. Stein CA and Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261:1004-1011.
47. Stull RA and Szoka FCJ (1995) Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm Res 12:465-483.
48. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz A and Calabretta B (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 258:562-565.
49. Tonkinson JL and Stein CA (1996) Antisense oligodeoxynucleotides as clinical therapeutic agents. Cancer Invest 14:54-65.
50. Twentyman PR, Rhodes T and Rayner A (1994) comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30:1360-1369.
51. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH and Marks JR (1995) Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci USA 92:8338-8342.
52. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335.
53. Walker S, Sofia MJ, Kakarla R, Kogan NA, Wierichs L, Longley CB, Bruker K, Axelrod HR, Midha S and Babu S (1996) Cationic facial amphiphiles: A promising class of transfection agents. Proc Natl Acad Sci USA 93:1585-1590.
54. Yu Y and Szoka FC (1996) Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35:5616-5623.
55. Zhang JT and Ling V (1991) Study of membrane orientation and glycosylation of extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem 266:18224-18232.